

## **2020 BIO CEO & Investor Conference Attendee List**

as of January 29, 2020

TITLE/INVESTOR TYPE	COMPANY	COUNTRY
VC/Corporate VC	3E Bioventures	United States
Family Office	3i Fund	United States
Family Office	A C Binder Corp	United States
Founder and Chair	Ab Studio	United States
Director	AbbVie	United States
VC/Corporate VC	Accelmed Partners	United States
VC/Corporate VC	Aceras Partners	United States
Executive Vice President, Chief Business Officer	Achillion Pharmaceuticals	United States
VC/Corporate VC	Acorn Bioventures	United States
Principal Financial Officer	Actinium Pharmaceuticals	United States
Chairman and CEO	Actinium Pharmaceuticals	United States
Family Office	Acuitas Capital Family Office	United States
VC/Corporate VC	Aditum Bio	United States
VC/Corporate VC	Adjuvant Capital	United States
CEO	Aetion	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Affinity Asset Advisors	United States
Family Office	AFUND	United States
CEO	Ai Cure Technologies	United States
VC/Corporate VC	AIG	United States
CEO	AIMM Therapeutics	Netherlands
VC/Corporate VC	Aisling Capital	United States
CEO	AiVita Biomedical	United States
Family Office	Aleph Capital	United States
Associate	Alexandria Venture Investments	United States
Head of LaunchLabs	Alexandria Venture Investments	United States
Family Office	Alignment Ventures	United States
Investor	Alliance for Aging Research	United States
Venture Philanthropy	Alliance for Cancer Gene Therapy	United States
Angel Investing	Alnitak capital	United States
SVP, Head of Medical Affairs	Alnylam Pharmaceuticals	United States
Chief Executive Officer	Alpha Cancer Technologies	Canada
Chairman	Alpha Cancer Technologies	Canada
VP of Business Development	Alpine Immune Sciences	United States
Chief Financial Officer	Altimmune	United States
President and CEO	Altimmune	United States
Chief Scientific Officer	Altimmune	United States
PRESIDENT/CEO	ALTuCELL	United States
CEO	Alveo Technologies	United States
President	Alveo Technologies	United States



10-11, 2020 • New York, NY New York Marriott Marquis

Chief Executive Officer	American Cone Technologies International	United States
CEO	American Gene Technologies International AMNICELL	United States
Founder and Chief Science Officer	AMNICELL	United States
		Canada
VC/Corporate VC	Amplitude Ventures	
President & CEO	Amplyx Pharmaceuticals	United States
CEO	Amygdala Neurosciences	United States
Chief Executive Officer	Anavex Life Sciences	United States
Investor	Andreessen Horowitz	United States
President & CEO	AnGes Inc.	Japan
Founder and CBO	AnHeart Therapeutics	United States
Co-founder and CEO	Anima Biotech	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Anson Funds	Canada
Vice President	Aon Risk Solutions	United States
Account Executive	Aon Risk Solutions	United States
Investment Officer	Apex-Brasil	Brazil
CEO	Aprinoia Therapeutics	Taiwan
President and Executive Director	Aptorum Group	Hong Kong
Senior Associate	Aptorum Group	Hong Kong
Head of Research & Development	Aptorum Group	Hong Kong
Chief Financial Officer	Aptose Biosciences	United States
Chairman & CEO	Aptose Biosciences	United States
Chief Business Officer	Aptose Biosciences	United States
CFO	Aracari Biosciences	United States
Family Office	Aracle Capital	United States
CEO	Arch Biopartners	Canada
VC/Corporate VC	Arch Venture Partners	United States
Founder, President & CEO	Arcturus Therapeutics	United States
Director, IR/PR/Marketing	Arcturus Therapeutics	United States
President and Chief Executive Officer	Arena Pharmaceuticals	United States
VC/Corporate VC	Arix Bioscience	United States
CEO	ARJUNA Therapeutics	Spain
Hedge/Mutual Funds (PM, Buy-Side Research)	Armistice Capital	United States
Royalty/Debt Financing	Arsenal Capital Partners	United States
CEO	Aruvant Sciences, Inc.	United States
Chief Business Officer	Ascendia Pharmaceuticals	United States
CEO	Ascendia Pharmaceuticals	United States
Sell-Side Research	Ascendiant Capital Markets	United States
Investment Bank	Ascendiant Capital Markets	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Ashford Capital Management	United States
Chief Business Officer	Ashvattha Therapeutics	United States
Chairman, CEO & President	Ashvattha Therapeutics	United States
Founder/CEO	Asimov	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Aspire Capital	United States
VC/Corporate VC	Asset Management Ventures	United States
VC/Corporate VC	Astellas Pharma US	United States
Angel Investing	Astute Capital	United States
VC/Corporate VC	ATEM Capital	United States
ver corporate ve	ATEINI Capitai	Officed States



A STATE OF THE PARTY OF THE PAR	
IDDED	A LANDER
	February 10-11, 2020 • New York, NY
	New York Marriott Marquis

		国制化
VC/Corporate VC	Atheneos Ventures	United States
CFO and GC	Atossa Genetics	United States
Chief Financial Officer	Atreca	United States
IR	Atreca	United States
Chief Strategy Officer	Atreca	United States
Chief Financial Officer	aTyr Pharma	United States
President, CEO	aTyr Pharma	United States
Royalty/Debt Financing	AUGC	Netherlands
Investor	Aurora Capitals	United States
Managing Director, LS Client Solutions	Avalere Health	United States
Head, Client Solutions	Avalere Health	United States
President and CEO	Avenue Therapeutics	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Ayrton Capital	United States
President and CEO	Azitra	United States
Chief Operating and Business Officer	AZTherapies	United States
Director, Business Development	AZTherapies	United States
VC/Corporate VC	Baidu	United States
Financial Advising	Bank of America Merrill Lynch	United States
Investor	Barclays	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Bathala Capital	United States
Family Office	Beacon Capital	United States
COO	Beacon Pharmaceutical	United States
Investment Bank	Berenberg Capital Markets	United States
Senior Manager/Area Manager UK	Berlin Partner für Wirtschaft und Technologie GmbH	Germany
Hedge/Mutual Funds (PM, Buy-Side Research)	Bifrost Capital	United States
Family Office	Bigger Capital Fund	United States
Family Office	BIMA Capital	United States
VC/Corporate VC	Bioadvance	United States
CEO	Bioasis Technologies	United States
Corporate Account Manager	BioCentury	United States
President & CEO	Biocept	United States
Investor	Biocoast Capital	United States
Angel Investing	BioIDEA	United States
Angel Investing	Bioldeations	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Bioldeations	United States
Senior Membership and BD Manager	Bioindustry Association (BIA)	United Kingdom
VC/Corporate VC	BioInnovation Capital	United States
VP Research and Development	BioLineRx	Israel
CEO	BioLineRx	Israel
President & CEO	BioMarker Strategies	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Biondo Investment Advisors	United States
VC/Corporate VC	Bios Partners	United States
Angel Investing	BioSense Global	United States
Family Office	Biotech Alliances International	United States
Family Office	Biotech Investment Group	United States
CEO and Co-founder	BioVersys AG	Switzerland
Family Office	Black Diamond Advisors	United States



A.S. B. Com	
lonno	ALL HILL
THE PARTY OF THE P	February 10-11, 2020 • New York, NY
	New York Marriott Marquis

	~ \ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	日 田川川 174、
Senior Health-Care Policy Analyst	Bloomberg Intelligence	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Blue Rock Capital Advisors	United States
Angel Investing	Bohe Angel Fund	China
VC/Corporate VC	Bojian Capital	United States
CEO	Boundless Bio	United States
VC/Corporate VC	Brace Pharma Capital	United States
Chief Operating Officer & Chief Medical Officer	BrainStorm Cell Therapeutics	United States
President & CEO	BrainStorm Cell Therapeutics	United States
Chief Executive Officer	Breakthrough Genomics	United States
Business Development	Brex	United States
Account Executive	Brex	United States
Investment Bank	Bridge Bank	United States
Royalty/Debt Financing	Bridge Bank	United States
Associate Director, External Operations	Bristol-Myers Squibb	United States
VP, Hematology, Cell Therapy & Translational Medicine	Bristol-Myers Squibb	United States
Angel Investing	Brock Capital Group	United States
Sell-Side Research	Brookline Capital Markets	United States
Sell-Side Research	Bryan, Garnier & Co.	United States
Sell-Side Research	BTIG	United States
Venture Partner	BVCF	United States
President & CEO	Caladrius Biosciences	United States
Vice President of IR & Corporate Communications	Caladrius Biosciences	United States
President & CEO	California Life Sciences Association	United States
Sell-Side Research	Canaccord Genuity	United States
Chief Executive Officer	Cancer Prevention Pharmaceuticals	United States
Sell-Side Research	Cantor	United States
Investor	Capital Family Office	United States
Director, Advanced Therapy Medicinal Product Development	Cardinal Health	United States
Chairman & CEO	Catalyst Pharmaceuticals	United States
COO & CSO	Catalyst Pharmaceuticals	United States
Bussiness developer	Catalyze NA	Netherlands
President	Catalyze NA	Netherlands
Family Office	Cato BioVentures	United States
Family Office	Caxton Alternative Management	United States
managing director	Cedrus Group	Hong Kong
Executive Vice President & Chief Scientific Officer	Celavie Biosciences	United States
VP Technology	Celavie Biosciences	United States
CEO/President	Celavie Biosciences	United States
Chief Executive Officer	Cell Care Therapeutics	United States
Chief Executive Officer	Celmatix	United States
Public Relations Contact	Cel-Sci	United States
Chief Executive Officer	CEL-SCI	United States
Partner	Centerview Partners	United States
CEO	Cerevance	United States
CEO	Cernostics	United States
CEO	CerSci Therapeutics	United States
Angel Investing	Chaperone Investment	United States



Indeal	
	February 10-11, 2020 • New York, NY New York Marriott Marquis

Call Cida Dagagrah	Chardan Capital Markets	United States
Sell-Side Research	·	United States United States
Family Office	Charlestown Capital Chartwell	
Hedge/Mutual Funds (PM, Buy-Side Research) Chief Executive Officer		United States
	ChemioCare	United States
Family Office	Chronon Capital	United States
Life Sciences Underwriter	Chubb	United States
Investor	Church Pension Fund	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	CJ Seligman & Co.	United States
Chief Executive Officer	Clearside Biomedical	United States
VC/Corporate VC	CLI	United States
Director	Clinical Network Services	United Kingdom
President & CEO	CODA Biotherapeutics	United States
Director, Investor Relations	CohBar	United States
Chief Operating Officer	CohBar	United States
CEO	CohBar Inc.	United States
Co-Founder and CSO	Concarlo Holdings	United States
Commercial Attaché of Lithuania to the USA	Consulate General of Lithuania	United States
President	Correlia Biosystems	United States
VC/Corporate VC	Cowen Healthcare Investments	United States
Angel Investing	Cowin Venture	China
Hedge/Mutual Funds (PM, Buy-Side Research)	Crescent Capital Ventures	United States
CEO / CMO	Cristal Therapeutics	Netherlands
CFO	Cristal Therapeutics	Netherlands
VC/Corporate VC	Crosswave Management	United States
Investor	CRV	United States
Investor	CSC Leasing	United States
VC/Corporate VC	CTI Capital Gestion	United States
VC/Corporate VC	CTTQ Pharmaceutical Group	United States
Angel Investing	CyberMed Holdings	United States
President & CEO	Cybrexa Therapeutics	United States
Executive Vice President, Finance & COO	Cyclacel Pharmaceuticals	United Kingdom
President & CEO	Cyclacel Pharmaceuticals	United States
Chief Executive Officer	Cytodel	United States
CEO	Cytonus Therapeutics	United States
VP Corporate Affairs	Cytovia Therapeutics	United States
Chairman & CEO	Cytovia Therapeutics	United States
Chief Executive Officer	Da Volterra	France
Investor	Dabar Investment Associates	United States
President & CEO	Daré Bioscience	United States
Investor	DB Capital	United States
VC/Corporate VC	Deca Ventures	United States
CEO	DeckTherapeutics	United States
Chief Business Officer	Decoy Biosystems	United States
VP, Business Development	Deerfield Management Company	United States
VC/Corporate VC	Deerfield Management Company	United States
Angel Investing	DEFTA Partners	United States
Venture Philanthropy	Delaware Innovation Space	United States
	2 Statiate Illiotation Space	J.iica Jiace



ALLE	
lones	
The state of the s	
	February 10-11, 2020 • New York, NY New York Marriott Marquis
-/ 1431	

President and CEO	DelMar Pharmaceuticals	United States
Investment Bank	Deltec Bank	Bahamas
Hedge/Mutual Funds (PM, Buy-Side Research)	Delwar Capital Management	United States
Sell-Side Research	Deutsche Bank	United States
VC/Corporate VC	DHVC	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	District 2 Capital	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Douglas C. Lane & Associates	United States
CEO	Drusolv Therapeutics	United States
Family Office	DTB Capital Management	United States
Chief Executive Officer	Dyadic International	United States
Chief Commercial Officer	Dyadic International	United States
VC/Corporate VC	Dynamk Capital	United States
CEO / Co-Founder	Dyve Biosciences	United States
Chief Operating Officer	Dyve Biosciences	United States
Family Office	E Squared Capital Management	United States
VC/Corporate VC	Easton Capital	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Edgewood Management	United States
President and CEO	eFFECTOR Therapeutics	United States
VC/Corporate VC	EG Capital Advisors	Russian Federation
CEO	Eleusis	United States
Vice President, Emerging Technology & Innovation	Eli Lilly and Company	United States
Sr. Director, Search & Evaluation - Immunology	Eli Lilly and Company	United States
Advisor, Search & Evaluation - Oncology	Eli Lilly and Company	United States
Director, Business Development	Eloxx Pharmaceuticals	United States
Chief Business Officer	Eloxx Pharmaceuticals	United States
CEO	Emerald Bioscience	United States
President, Co-founder and Chief Scientific Officer	ENB Therapeutics	United States
Investor Relations	Encore Advisory	United States
Chief Executive Officer	Enesi Pharma	United Kingdom
President, CEO & Founder	Engage Therapeutics	United States
Executive Vice President and Chief Operating Officer	Engage Therapeutics	United States
Chief Scientific Officer	Engrail Therapeutics	United States
President and CEO	Engrail Therapeutics	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Ensconce Capital	United States
CEO	Envisagenics	United States
Chief Executive Officer	EpicentRx	United States
CEO	EpiVax Oncology	United States
Chief Executive Officer	Equillium	United States
Family Office	Esousa Holdings	United States
Chief Executive Officer	E-Therapeutics	
	ETP Global Fund	United Kingdom United States
VC/Corporate VC		
CEO	Eupraxia Pharmaceuticals	Canada
Sell-Side Research	EVOLUTION Life Science Partners	United States
CEO	Evonetix	United Kingdom
CEO	EVQLV	United States
Angel Investing	Executive Forum Angels	United States
Family Office	Exome Asset Management	United States



	February 10-11, 2020 • New York, NY New York Marriott Marquis
Gate Pharmacouticals	United States

	~ \ \\ \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
President & CEO	EyeGate Pharmaceuticals	United States
Chief Financial Officer	EyeGate Pharmaceuticals	United States
VC/Corporate VC	Fannin Innovation Studio	United States
Family Office	FC Capital	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	First Island Capital	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	First Seafront Fund Management	China
CEO	First Wave	United States
Investor	FMG Ventures	United States
VC/Corporate VC	Fortress Biotech	United States
VC/Corporate VC	Fountain Healthcare Partners	Ireland
Family Office	Foxhill Asset Management	United States
Individual Investor	Franklin Global Partners	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Frigate Capital Management	United States
President, Biosciences Division	FSD Pharma	Canada
Executive Co-Chair & CEO	FSD Pharma	Canada
Capital Markets Associate	FSD Pharma	Canada
VC/Corporate VC	Fujifilm Diosynth Biotechnologies	United States
Financial Advising	Gagnon Securities	United States
General Manager	Gain Therapeutics	Switzerland
CEO	GBA Group Pharma	Austria
Advisor	Gedeon Richter	United States
President	Gedeon Richter USA	United States
Head, Oncology R&D	Geistlich Pharma NA	United States
Chief Executive Officer	Geistlich Pharma North America	United States
Head, Oncology Commercial Strategy	Geistlich Pharma North America	United States
CEO	Gel4Med	United States
VP of Investor Relations	Genfit Pharmaceuticals	United States
EVP Commercial Development	Genfit SA	France
CEO	Genfit SA	France
Executive Chairman	Genisphere	United States
Director, Life Sciences	Georgia, USA	United States
CEO	Gero	Singapore
SVP, Head of Corporate Communications	Global Blood Therapeutics	United States
VC/Corporate VC	Global Founders Capital	United States
Venture Philanthropy	Global Neurohealth Ventures	United States
CEO	Glycomine	United States
Chairman/CEO	Glycostem Therapeutics	Netherlands
Vice President, Business Development	Glysantis	Canada
CEO	Glysantis	Canada
President/CSO	Gnomegen	United States
Individual Investor	Golden Eagle Capital Advisors	United States
President & CEO	Goldilocks Therapeutics	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Goldwater Asset Management	United States
VC/Corporate VC	Good Health Capital	United States
Senior business development advisor	Government of Quebec	United States
CEO	Great Bay Bio Limited	Hong Kong
Executive Director	Greater Zurich Area Ag	United States



TES L	
	February 10-11, 2020 • New York, NY New York Marriott Marquis

VC/Corporate VC	GreenSky Capital	Canada
Chief Executive Officer	Greenwich LifeSciences	United States
VC/Corporate VC	Grey Sky Venture Partners	United States
Senior Managing Director	Griffin Securities	United States
President & Head of Investment Banking	H.C. Wainwright & Company	United States
Associate, Investment Banking	H.C. Wainwright & Company	United States
Director, Healthcare Investment Banking	H.C. Wainwright & Company	United States
Managing Director	H.C. Wainwright & Company	United States
Managing Director, Investment Banking	H.C. Wainwright & Company	United States
vice president	H.C. Wainwright & Company	United States
Investment Bank	H.C. Wainwright & Company	United States
Sell-Side Research	H.C. Wainwright & Company	United States
VC/Corporate VC	H.I.G. BioHealth Partners	United States
Venture Philanthropy	H.I.G. Capital Management	United States
VC/Corporate VC	H.I.G. Capital Management	United States
Family Office	Hannol Ventures	United States
VC/Corporate VC	Harbin Pharmaceutical Group	China
Chief Medical Officer	Harpoon Therapeutics	United States
VP Finance	Harpoon Therapeutics	United States
Family Office	Harvard Investors Group	United States
Strategic Partner	Headland Strategy Group	United States
Family Office	Health Innovative Technology	Hong Kong
Royalty/Debt Financing	HealthCare Royalty Partners	United States
VC/Corporate VC	HEDA Ventures	United States
Royalty/Debt Financing	Hercules Capital	United States
VC/Corporate VC	Hercules Capital	United States
Family Office	Hibiscus Bioventures	United States
VC/Corporate VC	HighCape Capital	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Highland Capital Management	United States
CEO	Histogen	United States
Managing Director	Hitech Health	Ireland
Royalty/Debt Financing	Horizon Technology Finance	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Hudson East Capital	United States
Venture Philanthropy	Hudson Square Capital	United States
VC/Corporate VC	Hyperplane	United States
CEO	Ichor Biologics	United States
Vice President	IDA Ireland	United States
CEO	Ilya Pharma	Sweden
Senior Vice President Corporate Development	Immunis.Al	United States
President and CEO	ImmunoMet Therapeutics	United States
CEO	Immunovant	United States
EVP Chief Business Officer	ImmunSYS	United States
Chairman & CEO	ImmunSYS	United States
Chief Business Officer	Impel NeuroPharma	United States
Director, Investor Relations & Communications	IMV	Canada
Chief Financial Officer	IMV	Canada
Hedge/Mutual Funds (PM, Buy-Side Research)	Inbio Ventures	Russian Federation



TES L	
	February 10-11, 2020 • New York, NY New York Marriott Marquis

President & CEO	InCarda Therapeutics	United States
Chief Executive Officer	Inflection Biosciences	Ireland
Product Specialist	Informa	United States
Investor	Ingenio Therapeutics / Mayewell Capital	United States
Family Office	InMed Pharmaceuticals	United States
Chief Financial Officer	INmune Bio	United States
President & CEO	INmune Bio	United States
VC/Corporate VC	Innovent Biologics	China
Investor	Integrium	United States
CEO	InteRNA Technologies B.V.	Netherlands
CEO	Inthera Bioscience AG	Switzerland
Hedge/Mutual Funds (PM, Buy-Side Research)	inThought Research	United States
CEO	Intract Pharma	United Kingdom
Director, R&D	Intract Pharma	United Kingdom
Investor	Intuitive	United States
Investor	Inukshuk Capital	United States
CEO	iQure Pharma	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	ISAR Capital Management	United States
MD, Investment Banking	J.P. Morgan	United States
Royalty/Debt Financing	J.P. Morgan	United States
VC/Corporate VC	J.W. Childs Associates	United States
Sell-Side Research	Janney Montgomery Scott	United States
Director, Licensing QS Evaluation	Janssen R&D	United States
Sell-Side Research	Jefferies	United States
Chairman	Jefferson Pharmaceuticals	United States
Financial Advising	JH Darbie & Co.	United States
CEO	JHL Biotech	Taiwan
Investor	Jiangsu Hengrui Medicine Co.	China
VC/Corporate VC	Jina Ventures	United States
Family Office	JM Cohen & Co.	United States
Individual Investor	Johnston Associates	United States
Royalty/Debt Financing	K2 HealthVentures	United States
Investor	Kalka Fund	United States
CEO	Katena Oncology	United States
Principal	Keynote Coaching	United States
Senior Vice President of Business Development	Kineta	United States
President	Kineta	United States
Chief Business Officer	Kintai Therapeutics	United States
President & CEO	Kintai Therapeutics	United States
President	Kissei America	United States
CEO	Kitov Pharma	Israel
President	Korea Drug Development Fund	Korea, Republic of
Hedge/Mutual Funds (PM, Buy-Side Research)	Krensavage Asset Management	United States
CEO, Cofounder	Kymeris	Canada
Sell-Side Research	Ladenburg Thalmann	United States
Sell-Side Research	Laidlaw & Company	United States
VC/Corporate VC	Laidlaw Venture Partners	United States



ALBERT	
lones	
	February 10-11, 2020 • New York, NY New York Marriott Marquis
	New Tork Marriott Marquis

Chairman (the Board Boardant and CEO	Landa Binda and	I I I I I I I I I I I I I I I I I I I
Chairman of the Board, President and CEO	Landos Biopharma	United States
Founder, Chairman & CEO	Lauren Sciences	United States
Account Director, IR & Corporate Communications	LaVoie Health Science	United States
Executive Vice President & Chief Strategy Officer	LaVoieHealthScience	United States
President & CEO	LaVoieHealthScience	United States
CEO	Leading BioSciences	United States
Chief Financial Officer	Leap Therapeutics	United States
CEO	Libera Bio	United States
Chief Editor	Life Science Connect	United States
VC/Corporate VC	Life Sciences Greenhouse of Central PA	United States
Investor	LifeNet Health	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	LifeScience EquityPartners	United States
Sell-Side Research	LifeTech Capital	United States
Chief Financial Officer	Liminal BioSciences	Canada
Chief Executive Officer	Liminal BioSciences	United Kingdom
Family Office	Lincoln Park Capital	United States
Family Office	Lions Bay Capital	United States
Investor	Livingston	United States
Managing Director, Global Head of Financing and Sales	Locust Walk	United States
Senior Vice President	Locust Walk	United States
CEO and Co-Founder	Locust Walk	United States
Angel Investing	LSWorks	United States
Family Office	LumeBio	Korea, Republic of
VC/Corporate VC	Lumira Ventures	United States
Investor	Lyfe Capital	United States
VC/Corporate VC	Lyfe Capital	United States
Director	MacDougall Biomedical Communications	United States
Senior Vice President	MacDougall Biomedical Communications	United States
VC/Corporate VC	Madryn Asset Management	United States
Royalty/Debt Financing	Madryn Asset Management	United States
Family Office	Magid Family Office	United States
Founder & CEO	MAIA Biotechnology	United States
Vice Chairman	Marcum	United States
Senior Director of Business Development	Marcum	United States
Partner	Marcum	United States
CEO	Matricelf	Israel
President & CEO	MaveriX Oncology	United States
President & CEO	MaxCyte	United States
Financial Advising	Maxim Group	United States
Investment Bank	Maxim Group	United States
Sell-Side Research	Maxim Group	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	MAZ Capital Advisors	United States
• • • • • • • • • • • • • • • • • • • •	Med Pro Investors	United States
Angel Investing CEO	MediSieve	
VC/Corporate VC	Merlin Nexus	United Kingdom United States
CEO		United States
	MetVital	
CEO	Microba	Australia



1 F B	
	February 10-11, 2020 • New York, NY New York Marriott Marquis

Investor	Mid Atlantic Bio Angels	United States
Chief Executive Officer	MimiVax	United States
SVP, Corp. Business Development	Mission Pharmacal	United States
Angel Investing	MIT Alumni Angels of Northern California	United States
VC/Corporate VC	Mitsui & Co. Global Investment	United States
Investor	Mizuho Corporate Bank	United States
Sell-Side Research	Mizuho Securities	United States
CEO	Modra Pharmaceuticals	Netherlands
CEO		United Kingdom
CEO	Mogrify Molecular Theranostics	United Kingdom  United States
Family Office	Morgan Capital	United States
Partner	Morrison & Foerster	United States
Partner	Morrison & Foerster	United States
Chief, Division of Liver Deseases	Mount Sinai School of Medicine	United States
Family Office	Mountain Brook Capital	United States
Director	Mucpharm	Australia
EVP, Chief Advocacy & Care Services Officer	Muscular Dystrophy Association	United States
Investor	MV Corp Services	United States
Investor	MVP Capital Partners	United States
SVP, Corporate Development	Nascent Biotech	United States
Acting Director Office of Translational Alliances & Coordination	National Heart, Lung, and Blood Institute	United States
Investor	National Holdings	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	NauVista Capital Management	United States
Chief Executive Officer	Navigen Pharmaceuticals	United States
Business Development / Attorney	NB Health Laboratory	Japan
VC/Corporate VC	NCL Technology Ventures	United States
CMO/CSO	NDA Group	United States
CEO	NDA Group	Sweden
Individual Investor	Needham & Co.	United States
Chief Medica Officer	Nektar Therapeutics	United States
Investment Bank	Network 1 Financial Securities	United States
Chief Executive Officer	Neumentum	United States
CEO	Neurogenesis	Israel
Chief Commercial & Head of Operations	NeuroRx	United States
Founder & CEO	NeuroRx	United States
Investor Principal	Neurotrope	United States
Principal Hodge / Mutual Funds (RM, Ruy, Side Research)	New Enterprise Associates  New Jersey Investment Division	United States United States
Hedge/Mutual Funds (PM, Buy-Side Research)  Angel Investing	,	United States United States
Family Office	New York Angels  Newburgh Bay Capital	United States  United States
President, Chief Medical Officer	NewLink Genetics	United States
CMO	Newron Pharmaceuticals	Italy
CEO	Newron Pharmaceuticals	Italy
CEO	NGM Biopharmaceuticals	United States
VC/Corporate VC	NGN Capital	United States  United States



long long	
	February 10-11, 2020 • New York, NY New York Marriott Marquis

Charterie Mewhating Analyst	Nika a la struma a str	United States
Strategic Marketing Analyst	Nikon Instruments	
Founder, President & CSO	Nirogyone Therapeutics	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Noble Equity Fund	United States
Family Office	Northlea Partners	United States
CEO	Notogen	Canada
Acting CEO and founder	Novadip Biosciences	Belgium
Investor	Novatio Ventures	United States
CEO	Novice Therapeutics	United States
VC/Corporate VC	Novo Ventures	United States
Chief Executive Officer	Now Biopharma	United States
VC/Corporate VC	NSIP	United States
Board Member	NYC Builds Bio+	United States
Financial Advising	NYC MedTech/Perselson	United States
Family Office	Oasis Capital	United States
Royalty/Debt Financing	Oberland Capital Management	United States
President	Oligomerix	United States
Chief Commercial Officer	Oligomerix	United States
Executive Vice President	Olipass	Korea, Republic of
CEO	OliPass	Korea, Republic of
VC/Corporate VC	Omega Funds	United States
Drug Discovery Business Development Director	Oncodesign	France
COO	Oncolyze	United States
President & CEO	Onconova Therapeutics	United States
President & CEO	ONL Therapeutics	United States
Chief Executive Officer	Opiant Pharmaceuticals	United States
Business Development Manager	OPIS	Italy
Global Head of Business Development	OPIS	Italy
Investor	Oppenheimer & Co.	United States
Family Office	Opto Capital Group	United States
Co-Founder	Opus Biotech Communications	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Oracle Partners	United States
Chief Executive Officer	Oragenics	United States
Chief Financial Officer	Oragenics	United States
Chief Executive Officer, President & Director	Oramed Pharmaceuticals	Israel
VC/Corporate VC	Orange Grove Bio	United States
Royalty/Debt Financing	OrbiMed Advisors	United States
VC/Corporate VC	OrbiMed Advisors	United States
Family Office	Orchard View Capital Advisors	United States
President, Chief Executive Officer and Director	Orgenesis	United States
Chief Executive Officer	OriCiro Genomics	Japan
CEO	Origenis Gmbh	Germany
Chief Business Officer	Origenis Gmbh	Germany
Chief Executive Officer	Oryzon Genomics	Spain
Investor	Otsuka Pharmaceutical Co.	United States
President and CEO	Outlook Therapeutics	United States
Chairman & CEO		
Chairman & CEO	Ovid Therapeutics	United States



ALC: Long	
TOTAL TOTAL	A STATE OF THE STA
	ebruary 10-11, 2020 New York, NY
A Marine Company of the Company of t	

	-/ M/N	
CEO	Oxidien Pharmaceuticals	United States
Royalty/Debt Financing	Pacific Western Bank	United States
VP of Business Development	PainQx	United States
CEO	PainQx	United States
CEO	Panorama Medicine	United States
VC/Corporate VC	Pappas Capital	United States
Chief Executive Officer	Paras Biopharmaceuticals Finland Oy	Finland
Chief Executive Officer	Paratek Pharmaceuticals	United States
Executive Director, IR and Corporate Communication	Paratek Pharmaceuticals	United States
Family Office	Park Ave. Capital Management International	United States
Investor	Parkman Healthcare Partners	United States
Family Office	Parkville Advisors	United States
CEO	Pattern Pharma	Canada
President and CEO	PDS Biotechnology Corporation	United States
Family Office	Peak One Investments	United States
Investor	Perseverance Capital Advisors	United States
Investor	Petrichor Healthcare Capital Management	United States
SVP & CSO, Internal Medicine	Pfizer	United States
Business Development	Pfizer	United States
Co-Founder & CEO	PhagoMed Biopharma GmbH	Austria
CEO	Phanes Therapeutics	United States
Account Manager	Pharma Intelligence - Informa	United States
VP, Business Development & Operations	PharmaDirections	United States
Royalty/Debt Financing	Pharmakon Advisors	United States
President & CEO	Phosplatin Therapeutics	United States
Chief Medical Officer	Phosplatin Therapeutics	United States
Executive Vice President & COO	Phosplatin Therapeutics	United States
Vice President of Commercialization	Phosplatin Therapeutics	United States
Vice President, Business Development	Phosplatin Therapeutics	United States
President & CEO	Pipeline Therapeutics	United States
Sell-Side Research	Piper Sandler	United States
Chief Financial Officer	Polynoma	United States
Chairman	Polynoma	United States
CSO	POP Biotechnologies	United States
Co-Founder / CEO	Praetego	United States
Investor	Premier Partners	Korea, Republic of
VC/Corporate VC	Prevail Partners	United States
Angel Investing	Princeton Biopharma	United States
President & CEO	Principia Biopharma	United States
Investor	Prism Biomedical Research	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Promethean Capital Group	United States
President & CEO	Protalix Biotherapeutics	Israel
CFO	Protalix Biotherapeutics	Israel
Founder and CEO	Quadrant Biosciences	United States
Investor	Quan Capital	China
CEO	Qulab	United States
Head of Business Development	RallyBio	United States
ricad of business bevelopilient	Nanybio	United States



President & Chief Executive Officer

VC/Corporate VC

Family Office

COM ENEMCE		HALL EN CENTRAL PROPERTY OF THE PARTY OF THE
	February	10-11, 2020 • New York, N
		New York Marriott Marqui
Sell-Side Research	Raymond James	United States
Managing Director, Co-Head of Health Care Investment Banking	Raymond James & Associates	United States
Director	Raymond James & Associates	United States
Co Founder and President	RBW Consulting	United States
Chief Executive Officer	Redx Pharma	United Kingdom
CEO	ReForm Biologics	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Remsen Investors	United States
CEO / FOUNDER	Rescue Hearing	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Revach Fund	United States
Chief Financial Officer	Rezolute	United States
Founder and CEO	RG+A	United States
Sell-Side Research	RHK Capital	United States
Investment Bank	RHK Capital	United States
Assistant Director, Business Development	RHO	United States
VP Finance	Ripple Therapeutics	Canada
President & CEO	Ripple Therapeutics	Canada
Chairman and Chief Executive Officer	RMJ Holdings	United States
Sell-Side Research	Robert W. Baird & Co.	United States
President & CEO	Rockwell Medical	United States
CFO	Rockwell Medical	United States
Family Office	Rolin	United States
VC/Corporate VC	Rosetta Capital	United Kingdom
Managing Director	ROTH Capital Partners	United States
Managing Director, Co-Head of Healthcare Investment Banking	ROTH Capital Partners	United States
Sell-Side Research	Roth Capital Partners	United States
CEO	RubrYc Therapeutics	United States
CSO	Rumi Scientific California	United States
President	Russo Partners	United States
Sell-Side Research	RW Baird	United States
Royalty/Debt Financing	Sagard Holdings	Canada
Chief Executive Officer	Salarius Pharmaceuticals	United States
President & CEO	Samus Therapeutics	United States
Chief Financial Officer	Samus Therapeutics	United States
Chief Scientific Officer	Samus Therapeutics	United States
Angel Investing	Sandhill Angels	United States
President of Sandoz US and Head of North America, Sandoz	Sandoz	United States
Director of Communications	Sandoz	United States
Head Business Development CDMO   North America	Sanofi US	United States
Sr. Business Development Manager CDMO	Sanofi US	United States
VC/Corporate VC	Santen Pharmaceutical Co.	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Sarissa Capital Management LP	United States
VC/Corporate VC	Satter Medical Technology Partnership	United States
CEO	Scancell	United Kingdom
Sr. VP - Business Development & Marketing	Schrocken	United States
I Been take at 0 Charles and at a Office a		III di a di Cuata a

Scynexis

SDIC Fund Management

Second Line Capital Management

**United States** 

**United States** 

China



· · · · · · · · · · · · · · · · · · ·	
In Hall	A ALLEH HAR
AN LEGET	
The Committee of the Co	
	E EN HAR BELLE
	February 10-11, 2020 • New York, NY New York Marriott Marquis
	New York Marriott Marquis

	*/\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
Investor	Sector Asset Management	Norway
Chief Executive Officer	Sengenics	Singapore
Co-Founder & CEO	SEngine Precision Medicine	United States
Chief Business Officer	SEngine Precision Medicine	United States
Chief Executive Officer	Serimmune	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Serrado Capital	United States
Lead Director, BD&L Oncology	Servier	France
Investor	Shanghai Henlius Biotech	United States
VP, Corp. Dev, & CFO, Investor	ShareVault	United States
Family Office	Shaw Strategic Capital	United States
C Suite Executive, Board Director	Shawn Tomasello Consulting	United States
Chairman	Shinkei Therapeutics	United States
Royalty/Debt Financing	Signature Bank	United States
Investor	Simcere Pharmaceutical Group	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Simrx Advisors	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Sio Capital Management	United States
Angel Investing	Sky Ventures Group	United States
CEO and President	SmartPharm Therapeutics	United States
VC/Corporate VC	Smilegate Investment	Korea, Republic of
Principal Principal	SMP Communications	United States
•	Sofinnova	United States
VC/Corporate VC		
VC/Corporate VC	Solar Capital Partners	United States
President & CEO	Soligenix	United States
Venture Philanthropy	Sound Affects	United States
Founder	Sparrow Pharmaceuticals	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Special Situations Funds	United States
Angel Investing	SPRIM Ventures	Singapore
Investor	SR One	United States
VC/Corporate VC	Starlink Capital	United States
Founder and President	Stemsynergy Therapeutics	United States
CEO	Step Pharma	France
Director, Life Sciences	Sterling Bay	United States
VC/Corporate VC	Stonehenge Capital	United States
VC/Corporate VC	Strathspey Crown	United States
Director, Investor Relations	Summit Therapeutics	United States
Chief Executive Officer	Summit Therapeutics	United Kingdom
Investor	Sun Pharmaceuticals	United States
Managing Director	SunTrust Robinson Humphrey	United States
Investor	SunTrust Robinson Humphrey	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Surveyor Capital	United States
Chief Executive Officer	Sutro Biopharma	United States
Trade Commissioner	Swiss Business Hub USA	United States
Chief Business Officer	SynDevRx	United States
Client Engagement Lead, Syneos One	Syneos Health	United States
President & CEO	Synlogic	United States
VP of IR & Corporate Communications	Synlogic	United States
Director, Investor Relations	Synthetic Biologics	United States



ALLE	
Tones Been	
	February 10-11, 2020 • New York, NY
	New York Marriott Marquis

CEO & CFO	Synthetic Biologics	United States
Founder & CEO	Synthis	United States
VC/Corporate VC	Taiho Ventures	United States
VC/Corporate VC	Tang Capital Management	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Tang Capital Management	United States
CEO	TargetGene Biotechnologies	Israel
VC/Corporate VC	Tectonic Capital	United States
Director Finance	TenNor Therapeutics	China
CEO	TenNor Therapeutics	China
President & COO	Teon Therapeutics	United States
Family Office	Terra Stone Capital	United States
CEO	Terran Biosciences	United States
Chief Business Officer	Terran Biosciences	United States
Chairman & CEO	Tetra Therapeutics	United States
President, Chief Executive Officer and Director	TFF Pharmaceuticals	United States
Angel Investing	The Abraham Group	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	The Anson Group	Canada
Family Office	The Astrologers Fund	United States
Sell-Side Research	The Benchmark Company	United States
Investor	The Center for Performance Investing	United States
Investor	The Engine	United States
Investment Associate	The Global Emerging Market (GEM) Group	United States
Venture Philanthropy	The Leukemia & Lymphoma Society	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	The Lind Partners	United States
Managing Partner	The Money Channel NYC	United States
Chief Business Development Officer	The Money Channel NYC	United States
Chairman of the Board	TheraTarget	United States
Sell-Side Research	Think Equity	United States
Administrative Dept.	Thoth Science	Korea, Republic of
Executive Vice President And COO	Tiberend Strategic Advisors	United States
President & CEO	Tiberend Strategic Advisors	United States
CSO	TnA Therapeutics	United States
Investor	Tokyo Stock Exchange	Japan
Chief Executive Officer	TONIX Pharmaceuticals	United States
Managing Director	Torreya	United States
Partner	Torreya	United States
VC/Corporate VC	Tosoh USA	United States
Angel Investing	Treehill Principal Strategies	United Kingdom
Strategic Partnerships Manager	TrialSpark	United States
Angel Investing	Tri-Medix	United States
Chief Scientific Officer	TriSalus Life Sciences	United States
President & CEO	TriSalus Life Sciences	United States
Chief Executive Officer and Chairman	TrovaGene	United States
Chief Scientific Officer	TrovaGene	United States
Investor	Tryphon Capital Advisors	United States
Chief Business Officer	Tulane University	United States
Senior Vice President Biopharma BD	twoXAR	United States



1-8-8	
Innananana.	
Tones.	441113333
A RESEN	30
TRANSPORTER	相比的
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	THE RAIL HE LEFT
The state of the s	
74/1/2 100	February 10-11, 2020 • New York, NY
	New York Marriott Marquis
~/\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	

+ + + + + + + + + + + + + + + + + + + +	~/\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	国 用 124、
CEO	twoXAR	United States
Technical Specialist & Entrepreneurial Lead	University of Exeter	United Kingdom
Endowment/Foundation	University of Notre Dame	United States
Manager, Strategic Industry Ventures	University of Texas, MD Anderson Cancer Center	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Unterberg Capital	United States
Family Office	Upstream Partners	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	V2m Life Sciences Fund	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	ValQuest	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Varana Capital	United States
СВО	Vaximm AG	Switzerland
CEO	VBL Therapeutics	Israel
Family Office	Vector Capital	United States
Angel Investing	Vector Point Ventures	United States
Family Office	Vector Resource Funds	United States
President and CEO	VenatoRx Pharmaceuticals	United States
Chief Business Officer	VenatoRx Pharmaceuticals	United States
Business Development Manager	Venture Valuation	Switzerland
Founder & CEO	Verlmmune	United States
CEO	Verum Diagnostics	United States
Founder & CSO	Verum Diagnostics  Verum Diagnostics	United States
		<b>+</b>
President & CEO	Vida Strategic Partners	United States
President & CEO	viDA Therapeutics	Canada
Director	Vida Ventures	United States
Managing Director	Vida Ventures	United States
Senior Strategic Advisor	Vigeo Therapeutics	United States
Senior VP Finance	Viking Therapeutics	United States
Chief Financial officer	Viracta Therapeutics	United States
Family Office	Vista Capital Advisors	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Vista Point Capital	United States
CEO	Vita Therapeutics	United States
Investor	Voya Financial	United States
President and CEO	Vyome Therapeutics	United States
Investor	W Global Capital	United States
Investment Bank	Wallachbeth Capital	United States
Sell-Side Research	WBB Securities	United States
Family Office	Western International	United States
VC/Corporate VC	Westlake Ventures	United States
CEO	Westwood Therapeutics	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Wexford Capital	United States
Family Office	Wick Capital Partners	United States
Investor	Wolpert Associates	United States
Executive Director	Women In Bio	United States
Co-Founder, President & CEO	X-Biotix Therapeutics	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	Xeraya Capital Life Venture	Malaysia
Family Office	Xerion Investments	United States
President & CEO	XyloCor Therapeutics	United States
Hedge/Mutual Funds (PM, Buy-Side Research)	YA Global	United States



February 10-11, 2020	· New York, NY
New Yorl	Marriott Marquis

		100 III F & N & N
Blavatnik Fellow	Yale University	United States
Endowment/Foundation	Yale University, Office of Cooperative Research	United States
CEO	Yamo Pharmaceuticals	United States
Individual Investor	YILGA Management Services	Israel
Independent Research Firm	Young America Capital	United States
Sell-Side Research	Zacks Small Cap Research	United States
VC/Corporate VC	Zeniths Capital	China
President and CEO	Zikani Therapeutics	United States
Investor	ZJ Future	United States